The SOSV Climate Tech Summit Agenda is now live! Register Now

Prothegen

Therapeutics to inhibit and promote ferroptosis

Team

Scott Dixon

CSO

Davide Zanchi

CEO

Company details

Prothegen is developing therapeutics to inhibit or promote ferroptosis, a new type of cell death involved in major life-threatening diseases. Ferroptosis is an iron-mediated failure of antioxidant defenses. Now, Prothegen is developing drugs that stop cells from dying of ferroptosis.

Get In Touch with Prothegen

Please tell us a little bit about yourself and why you'd like to get connected. Prothegen + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.